Searched for: in-biosketch:yes
person:morgag04
Cure-Rate Survival Models and Their Application to Cancer Clinical Trials
Chapter by: Othus, Megan; Mitchell, Alan; Barlogie, Bart; Morgan, Gareth; Crowley, John
in: Frontiers of biostatistical methods and applications in clinical oncology by Matsui, Shigeyuki; Crowley, John (Eds)
Singapore : Springer, [2017]
pp. 165-178
ISBN: 9789811001260
CID: 3708772
Optimal Three-Group Splits Based on a Survival Outcome
Chapter by: Crowley, John; Mitchell, Alan; Qu, Pingping; Morgan, Gareth; Barlogie, Bart
in: Frontiers of biostatistical methods and applications in clinical oncology by Matsui, Shigeyuki; Crowley, John (Eds)
Singapore : Springer, [2017]
pp. 231-242
ISBN: 9789811001260
CID: 3708782
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
Mohan, Meera; Buros, Amy; Mathur, Pankaj; Gokden, Neriman; Singh, Manisha; Susanibar, Sandra; Jo Kamimoto, Jorge; Hoque, Shadiqul; Radhakrishnan, Muthukumar; Matin, Aasiya; Davis, Cynthia; Grazziutti, Monica; Thanendrarajan, Sharmilan; van Rhee, Frits; Zangari, Maurizio; Davies, Faith; Morgan, Gareth; Epstein, Joshua; Barlogie, Bart; Schinke, Carolina
Light chain deposition disease (LCDD) is characterized by monotypic immunoglobulin depositions which will eventually lead to loss of organ function if left untreated. While the kidney is almost always affected, the presence and degree of LCDD in other organs vary. Ten to thirty percent of LCDD patients have underlying Multiple Myeloma (MM), yet outcome and prognostic markers in this particular patient group are still lacking. Here, we analyzed 69 patients with MM and biopsy proven LCDD and report on renal and extra-renal involvement and its impact on prognosis as well as renal response depending on hematologic response. Coexisting light chain diseases such as AL amyloid and cast nephropathy were found in 30% of patients; those with LCDD and concurrent amyloid tended to have shorter survival. Cardiac involvement by LCDD was seen in one-third of our patients and was associated with shorter overall survival; such patients also had a significantly higher risk of treatment-related mortality (TRM) after stem cell transplant (SCT) compared to LCDD patients without cardiac involvement. This study highlights that MM patients with LCDD present with different clinical features compared to previously reported LCDD cohorts. Rapid initiation of treatment is necessary to prevent progressive renal disease and worse outcome. Coexisting light chain diseases and cardiac involvement are more common than previously reported and confer worse clinical outcome, emphasizing the need for careful patient careful patient evaluation and treatment selection.
PMID: 28383130
ISSN: 1096-8652
CID: 3695362
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
Pawlyn, C; Bright, M D; Buros, A F; Stein, C K; Walters, Z; Aronson, L I; Mirabella, F; Jones, J R; Kaiser, M F; Walker, B A; Jackson, G H; Clarke, P A; Bergsagel, P L; Workman, P; Chesi, M; Morgan, G J; Davies, F E
Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approaches are, therefore, required. A growing number of epigenetic inhibitors are now available including EZH2 inhibitors that are in early-stage clinical trials for treatment of haematological and other cancers with EZH2 mutations or in which overexpression has been correlated with poor outcomes. For the first time, we have identified and validated a robust and independent deleterious effect of high EZH2 expression on outcomes in myeloma patients. Using two chemically distinct small-molecule inhibitors, we demonstrate a reduction in myeloma cell proliferation with EZH2 inhibition, which leads to cell cycle arrest followed by apoptosis. This is mediated via upregulation of cyclin-dependent kinase inhibitors associated with removal of the inhibitory H3K27me3 mark at their gene loci. Our results suggest that EZH2 inhibition may be a potential therapeutic strategy for the treatment of myeloma and should be investigated in clinical studies.
PMCID:5380911
PMID: 28362441
ISSN: 2044-5385
CID: 3695352
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests
Heaney, Jennifer L J; Campbell, John P; Griffin, Anne E; Birtwistle, Jane; Shemar, Meena; Child, J Anthony; Gregory, Walter M; Cairns, David A; Morgan, Gareth; Jackson, Graham; Drayson, Mark T
This study aims to guide the integration of serum free light chain (sFLC) tests into clinical practice, including a new rapid test (Seralite® ). Blood and urine analysis from 5573 newly diagnosed myeloma patients identified 576 light chain only (LCO) and 60 non-secretory (NS) cases. Serum was tested by Freelite® and Seralite® at diagnosis, maximum response and relapse. 20% of LCO patients had urine FLC levels below that recommended for measuring response but >97% of these had adequate sFLC levels (oligosecretory). The recommended Freelite® sFLC ≥100 mg/l for measuring response was confirmed and the equivalent Seralite® FLC difference (dFLC) >20 mg/l identified. By both methods, ≥38% of NS patients had measurable disease (oligosecretory). Higher sFLC levels were observed on Freelite® at all time points. However, good clinical concordance was observed at diagnosis and in response to therapy. Achieving at least a very good partial response according to either sFLC method was associated with better patient survival. Relapse was identified using a Freelite® sFLC increase >200 mg/l and found 100% concordance with a corresponding Seralite® dFLC increase >30 mg/l. Both Freelite® and Seralite® sensitively diagnose and monitor LCO/oligosecretory myeloma. Rapid testing by Seralite® could fast-track FLC screening and monitoring. Response by sFLC assessment was prognostic for survival and demonstrates the clinical value of routine sFLC testing.
PMID: 28573706
ISSN: 1365-2141
CID: 3695372
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
Chavan, S S; He, J; Tytarenko, R; Deshpande, S; Patel, P; Bailey, M; Stein, C K; Stephens, O; Weinhold, N; Petty, N; Steward, D; Rasche, L; Bauer, M; Ashby, C; Peterson, E; Ali, S; Ross, J; Miller, V A; Stephens, P; Thanendrarajan, S; Schinke, C; Zangari, M; van Rhee, F; Barlogie, B; Mughal, T I; Davies, F E; Morgan, G J; Walker, B A
The purpose of this study is to identify prognostic markers and treatment targets using a clinically certified sequencing panel in multiple myeloma. We performed targeted sequencing of 578 individuals with plasma cell neoplasms using the FoundationOne Heme panel and identified clinically relevant abnormalities and novel prognostic markers. Mutational burden was associated with maf and proliferation gene expression groups, and a high-mutational burden was associated with a poor prognosis. We identified homozygous deletions that were present in multiple myeloma within key genes, including CDKN2C, RB1, TRAF3, BIRC3 and TP53, and that bi-allelic inactivation was significantly enriched at relapse. Alterations in CDKN2C, TP53, RB1 and the t(4;14) were associated with poor prognosis. Alterations in RB1 were predominantly homozygous deletions and were associated with relapse and a poor prognosis which was independent of other genetic markers, including t(4;14), after multivariate analysis. Bi-allelic inactivation of key tumor suppressor genes in myeloma was enriched at relapse, especially in RB1, CDKN2C and TP53 where they have prognostic significance.
PMCID:5386330
PMID: 28234347
ISSN: 2044-5385
CID: 3695332
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma
da Silva Filho, M I; Försti, A; Weinhold, N; Meziane, I; Campo, C; Huhn, S; Nickel, J; Hoffmann, P; Nöthen, M M; Jöckel, K-H; Landi, S; Mitchell, J S; Johnson, D; Morgan, G J; Houlston, R; Goldschmidt, H; Jauch, A; Milani, P; Merlini, G; Rowcieno, D; Hawkins, P; Hegenbart, U; Palladini, G; Wechalekar, A; Schönland, S O; Hemminki, K
Immunoglobulin light chain (AL) amyloidosis is characterized by tissue deposition of amyloid fibers derived from immunoglobulin light chain. AL amyloidosis and multiple myeloma (MM) originate from monoclonal gammopathy of undetermined significance. We wanted to characterize germline susceptibility to AL amyloidosis using a genome-wide association study (GWAS) on 1229 AL amyloidosis patients from Germany, UK and Italy, and 7526 healthy local controls. For comparison with MM, recent GWAS data on 3790 cases were used. For AL amyloidosis, single nucleotide polymorphisms (SNPs) at 10 loci showed evidence of an association at P<10-5 with homogeneity of results from the 3 sample sets; some of these were previously documented to influence MM risk, including the SNP at the IRF4 binding site. In AL amyloidosis, rs9344 at the splice site of cyclin D1, promoting translocation (11;14), reached the highest significance, P=7.80 × 10-11; the SNP was only marginally significant in MM. SNP rs79419269 close to gene SMARCD3 involved in chromatin remodeling was also significant (P=5.2 × 10-8). These data provide evidence for common genetic susceptibility to AL amyloidosis and MM. Cyclin D1 is a more prominent driver in AL amyloidosis than in MM, but the links to aggregation of light chains need to be demonstrated.
PMID: 28025584
ISSN: 1476-5551
CID: 3695322
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Rasche, L; Chavan, S S; Stephens, O W; Patel, P H; Tytarenko, R; Ashby, C; Bauer, M; Stein, C; Deshpande, S; Wardell, C; Buzder, T; Molnar, G; Zangari, M; van Rhee, F; Thanendrarajan, S; Schinke, C; Epstein, J; Davies, F E; Walker, B A; Meissner, T; Barlogie, B; Morgan, G J; Weinhold, N
In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site is well-perfused, a rapid dissemination of "fitter" clones may be anticipated. However, an imbalanced distribution of multiple myeloma is frequently observed in medical imaging. Here, we perform multi-region sequencing, including iliac crest and radiology-guided focal lesion specimens from 51 patients to gain insight into the spatial clonal architecture. We demonstrate spatial genomic heterogeneity in more than 75% of patients, including inactivation of CDKN2C and TP53, and mutations affecting mitogen-activated protein kinase genes. We show that the extent of spatial heterogeneity is positively associated with the size of biopsied focal lesions consistent with regional outgrowth of advanced clones. The results support a model for multiple myeloma progression with clonal sweeps in the early phase and regional evolution in advanced disease. We suggest that multi-region investigations are critical to understanding intra-patient heterogeneity and the evolutionary processes in multiple myeloma.In multiple myeloma, malignant cells expand within bone marrow. Here, the authors use multi-region sequencing in patient samples to analyse spatial clonal architecture and heterogeneity, providing novel insight into multiple myeloma progression and evolution.
PMCID:5559527
PMID: 28814763
ISSN: 2041-1723
CID: 3695412
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach [Letter]
Went, M; Sud, A; Law, P J; Johnson, D C; Weinhold, N; Försti, A; van Duin, M; Mitchell, J S; Chen, B; Kuiper, R; Stephens, O W; Bertsch, U; Campo, C; Einsele, H; Gregory, W M; Henrion, M; Hillengass, J; Hoffmann, P; Jackson, G H; Lenive, O; Nickel, J; Nöthen, M M; da Silva Filho, M I; Thomsen, H; Walker, B A; Broyl, A; Davies, F E; Langer, C; Hansson, M; Kaiser, M; Sonneveld, P; Goldschmidt, H; Hemminki, K; Nilsson, B; Morgan, G J; Houlston, R S
PMCID:5520395
PMID: 28622301
ISSN: 2044-5385
CID: 3695392
Differentiation stage of myeloma plasma cells: biological and clinical significance
Paiva, B; Puig, N; Cedena, M T; de Jong, B G; Ruiz, Y; Rapado, I; Martinez-Lopez, J; Cordon, L; Alignani, D; Delgado, J A; van Zelm, M C; Van Dongen, J J M; Pascual, M; Agirre, X; Prosper, F; MartÃn-Subero, J I; Vidriales, M-B; Gutierrez, N C; Hernandez, M T; Oriol, A; Echeveste, M A; Gonzalez, Y; Johnson, S K; Epstein, J; Barlogie, B; Morgan, G J; Orfao, A; Blade, J; Mateos, M V; Lahuerta, J J; San-Miguel, J F
The notion that plasma cells (PCs) are terminally differentiated has prevented intensive research in multiple myeloma (MM) about their phenotypic plasticity and differentiation. Here, we demonstrated in healthy individuals (n=20) that the CD19-CD81 expression axis identifies three bone marrow (BM)PC subsets with distinct age-prevalence, proliferation, replication-history, immunoglobulin-production, and phenotype, consistent with progressively increased differentiation from CD19+CD81+ into CD19-CD81+ and CD19-CD81- BMPCs. Afterwards, we demonstrated in 225 newly diagnosed MM patients that, comparing to normal BMPC counterparts, 59% had fully differentiated (CD19-CD81-) clones, 38% intermediate-differentiated (CD19-CD81+) and 3% less-differentiated (CD19+CD81+) clones. The latter patients had dismal outcome, and PC differentiation emerged as an independent prognostic marker for progression-free (HR: 1.7; P=0.005) and overall survival (HR: 2.1; P=0.006). Longitudinal comparison of diagnostic vs minimal-residual-disease samples (n=40) unraveled that in 20% of patients, less-differentiated PCs subclones become enriched after therapy-induced pressure. We also revealed that CD81 expression is epigenetically regulated, that less-differentiated clonal PCs retain high expression of genes related to preceding B-cell stages (for example: PAX5), and show distinct mutation profile vs fully differentiated PC clones within individual patients. Together, we shed new light into PC plasticity and demonstrated that MM patients harbouring less-differentiated PCs have dismal survival, which might be related to higher chemoresistant potential plus different molecular and genomic profiles.
PMCID:5439510
PMID: 27479184
ISSN: 1476-5551
CID: 3695272